News

Astellas And Pfizer's XTANDITM (Enzalutamide) Shows Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk o ...